News
Australia recommends AstraZeneca COVID-19 vaccine only for people over 60
The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended the use of the AstraZeneca Covid-19 vaccine in Australia for individuals aged above 60 years.
The latest advice is based on the increased risk of illness and death from Covid-19...
News
European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine, including the ability to purchase other COVID-19 vaccine candidates from Moderna’s...
News
Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
Tonix Pharmaceuticals has announced its intention to develop the investigational candidate TNX-102 for the potential treatment of long COVID syndrome – also known as Post-Acute Sequelae of COVID-19 (PASC).
Currently, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is in mid-phase 3...
Drug Research
Fujitsu Japan Embarks on Joint Research for COVID-19 Therapies Using Fugaku
Fujitsu Japan Limited announced that it will initiate a new research project with a research team led by Takefumi Yamashita, Project Associate Professor of Research Center for Advanced Science and Technology (RCAST) , the University of Tokyo utilizing the...
News
What Medical Supplies Should Companies Provide To Employees
The COVID-19 pandemic has stopped most businesses with the strict guideline of social distancing and staying at home, thus many have lost their livelihood. Those companies that are still open are now left with the responsibility to protect their...
Drug Research
Coriolis Pharma Expands ATMP Development Facilities
Coriolis Pharma, a provider of research and development of for (bio)pharmaceutical drugs, is expanding its advanced therapy medicinal products (ATMP) development facilities under biosafety level S2 (BSL2 / S2).
Re-construction of an existing building near the Coriolis headquarters started in...
Clinical Trials
Vectura, Incannex Enter Preclinical Services Agreement
Vectura Group plc, an inhalation CDMO, has signed an agreement with Incannex Healthcare Ltd., an Australian cannabinoid medicines development company, to provide preclinical development services for IHL-216A, Incannex’s proprietary inhaled drug product for the treatment of traumatic brain injury...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read